Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Feb 2022
NICE recommends new drug for people living with obesity
8 February 2022 - Thousands of people living with obesity are set to benefit from a new drug which has helped ...
Posted by Michael Wonder on 08 Feb 2022
Cannabis-based medicine among batch of new drugs approved for use in Scotland
8 February 2022 - The medicines have been approved for use by the Scottish Medicines Consortium. ...
Posted by Michael Wonder on 08 Feb 2022
Pharmacist substitution of PBS medicines without a prescription during shortages (Serious Scarcity Substitution Instrument) - 8 February 2022
8 February 2022 - From 8 February 2022, abatacept syringe (Orencia) and abatacept auto-injector (Orencia ClickJect) can be interchangeably substituted ...
Posted by Michael Wonder on 07 Feb 2022
Review of the National Medicines Policy – consultation on draft National Medicines Policy extended
8 February 2022 - The consultation period on the draft NMP was due to close on Wednesday 16 February 2022. ...
Posted by Michael Wonder on 07 Feb 2022
Mentoring as a potential means to assist consumer representatives contribute effectively to the assessment of health technologies in Australia: a pragmatic review
7 February 2022 - This project was implemented on behalf of the Health Technology Assessment Consumer Consultative Committee to explore training ...
Posted by Michael Wonder on 07 Feb 2022
Why so few value assessments on health services and procedures, and what should be done?
4 February 2022 - The field of cost effectiveness analysis has grown rapidly but in somewhat lopsided fashion. ...
Posted by Michael Wonder on 07 Feb 2022
EQRx seeks to establish a more competitive market for oncology drugs in the U.S.
7 February 2022 - In 2017, every new cancer drug approved in the U.S. had a launch price over $100,000. And ...
Posted by Michael Wonder on 07 Feb 2022
NGM Bio’s NGM621 receives fast track designation from the FDA for the treatment of patients with geographic atrophy secondary to age-related macular degeneration
7 February 2022 - NGM Biopharmaceuticals today announced that the U.S. FDA has granted fast track designation to NGM621, a monoclonal ...
Posted by Michael Wonder on 07 Feb 2022
Azurity Pharmaceuticals announces FDA approval of Fleqsuvy (baclofen oral suspension)
7 February 2022 - Azurity Pharmaceuticals today announced the U.S. FDA approval of Fleqsuvy (baclofen) 25 mg/5 mL concentrated suspension for ...
Posted by Michael Wonder on 07 Feb 2022
Everest Medicines announces first drug approval of Trodelvy in Singapore for second-line metastatic triple negative breast cancer
6 February 2022 - Singapore Health Sciences Authority approval marks the first in a series of expected approvals of Trodelvy ...
Posted by Michael Wonder on 07 Feb 2022
Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract
7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab). ...
Posted by Michael Wonder on 07 Feb 2022
Not so NICE: cancer patients miss out on innovative new treatments
7 February 2022 - Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes ...
Posted by Michael Wonder on 07 Feb 2022
SMC - February 2022 decisions
7 February 2022 - Advice on six new medicines for use in conditions including a rare lung cancer caused by ...
Posted by Michael Wonder on 07 Feb 2022
Analysis of consumer comments into PBAC decision-making (2014–9)
4 February 2022 - Our objective was to analyse and review consumer comments in the PBAC's decision-making process. ...
Posted by Michael Wonder on 07 Feb 2022
Bladder cancer technology: new improved blue light cystoscopy system receives FDA approval for use in non-muscle invasive bladder cancer in the U.S.
7 February 2022 - Photocure announces U.S. FDA approval of a new and improved blue light system to be used with ...